You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Genome-wide association studies offer a look at the rare and common contributors to the heart condition, pointing to possible prediction and treatment tools.
By uncovering genetic factors behind blood and urine biomarkers, researchers came up with polygenic scores related to biomarker status and related disease risk.
The African health technology company 54gene is eager for partnerships with researchers and biopharmaceutical companies alike.
Researchers identified several immune-related genes in a GWAS that included more than 2,200 COVID-19 patients treated in UK intensive care units.
Data presented at the ASHG virtual meeting highlighted the population insights that can be gleaned from IDB profiles in populations, including loci linked to blood traits.
Researchers reported shared and distinct genetic contributors to systemic lupus erythematosus in individuals with African or European ancestry.
With array and exome data, Australian investigators saw apparent ties between amelanotic/hypomelanotic melanoma and rare albinism gene changes.
Using genome-wide association study, cell line, organoid, and other data, researchers tracked down polygenic contributors to drug-induced liver injury in hepatocytes.
A spontaneous coronary condition that is overrepresented in young women had a polygenic risk score linked to lower-than-usual atherosclerosis-related heart disease risk.
Two new papers have identified thousands of genetic loci with ties to more than two-dozen blood cell traits in individuals from up to five ancestry groups.
Imperial College London researchers are shifting away from testing a COVID-19 vaccine to focus on combating newly emerging SARS-CoV-2 variants, the Independent says.
According to the Associated Press, genetic genealogy has helped law enforcement officials identify an unknown victim of the Green River Killer.
In PNAS this week: target to reduce chemotherapy-induced cardiac injury, tool finds ancient endogenous RNA viruses, and more.
Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.